Harbor Investment Advisory’s VanEck Pharmaceutical ETF PPH Stock Holding History

Harbor Investment Advisory’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	-$191	–	1411
2024 Q1	$191	Hold	2	–	–	﹤0.01%	1293
2023 Q4	$170	Hold	2	–	–	﹤0.01%	1136
2023 Q3	$166	Hold	2	–	–	﹤0.01%	1156
2023 Q2	$163	Hold	2	–	–	﹤0.01%	1314
2023 Q1	$160	Hold	2	–	–	﹤0.01%	1307
2022 Q4	$159	Hold	2	–	–	﹤0.01%	1313
2022 Q3	$0	Hold	2	–	–	﹤0.01%	1379
2022 Q2	$0	Hold	2	–	–	﹤0.01%	1386
2022 Q1	$0	Hold	2	–	–	﹤0.01%	1381
2021 Q4	$0	Hold	2	–	–	﹤0.01%	1350
2021 Q3	$0	Hold	2	–	–	﹤0.01%	1346
2021 Q2	$0	Buy	+2	New	+$143	﹤0.01%	1294

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

FPGK

Financial Partners Group (Kansas) Overland Park, Kansas $836M AUM 21.04% 1-Year Est. Return

Harbor Investment Advisory's PPH Position: Q2 2024 in Review

Harbor Investment Advisory sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 2 shares — an estimated $191 sold.

Harbor Investment Advisory first reported a position in PPH in Q2 2021 and held it in 12 quarters. The position peaked at $191 in Q1 2024. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

Harbor Investment Advisory reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
Harbor Investment Advisory sold 2 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $191.
Harbor Investment Advisory first reported a position in VanEck Pharmaceutical ETF in Q2 2021 and held it in 12 quarters.
Harbor Investment Advisory's VanEck Pharmaceutical ETF position peaked at $191 in Q1 2024.
140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Harbor Investment Advisory's 13F filing for Q2 2024, filed 19 Jul 2024.